Navigation Links
WorldHeart Appoints New President and CEO
Date:2/6/2009

SALT LAKE CITY, Feb. 6 /PRNewswire-FirstCall/ -- World Heart Corporation ("WorldHeart", Nasdaq: WHRT), a pioneer in cardiac assist technologies, announced today that it has appointed John Alexander ("Alex") Martin as President and CEO. Mr. Martin also replaced Jal S. Jassawalla on the Board of Directors. Mr. Martin joins WorldHeart from Edwards Lifesciences where he was President of the North American Region and Corporate Vice President since 2004. Previously, Alex was with Cordis Corporation, a Johnson and Johnson (J&J) company, where he served as Senior Vice President of International and prior to that, Vice President of Sales and Marketing. At Cordis, he had responsibility for all U.S. coronary therapeutic and diagnostic device sales and under his leadership the company experienced significant growth and became the market leader. Alex was responsible for the launch of the first commercialized drug-eluting stent in the US while at Cordis.

Before Cordis, Mr. Martin, 55, served in sales, marketing and business development management positions at several organizations, including C.R. Bards' USCI division, Cambridge Heart and IMED Corporation. He also served as Director of the Emergency Medical Services at The Medical Center at Bowling Green. Mr. Martin earned a bachelor's degree from the University of Kentucky at Lexington.

Jal S. Jassawalla, WorldHeart's President and CEO since 2004 and co-founder of the original Novacor Medical Corporation, commented that, "I join WorldHeart's Board of Directors and employees in welcoming Alex to WorldHeart and the exciting and promising field of circulatory assist therapy." Mr. Jassawalla will continue in a senior role as Executive Vice President and Chief Technology Officer. His emphasis will be on research & development, product strategy, and clinical and regulatory affairs.

"We are pleased to have Alex Martin join WorldHeart," said Michael Estes, Chair of WorldHeart's Board of Directors. "Alex's extensive background in medical technologies and long-standing relationships within the cardiovascular community will be particularly valuable as WorldHeart brings its Levacor technology into the clinical arena and continues to advance its unique 'mag-lev' technology platform. The Board of Directors is also very pleased that Jal Jassawalla will continue in his key role as Executive Vice President of WorldHeart."

About World Heart Corporation

WorldHeart is a developer of mechanical circulatory support systems. WorldHeart is headquartered in Salt Lake City, Utah with additional facilities in Oakland, California, USA and Herkenbosch, The Netherlands. WorldHeart's registered office is in Ottawa, Ontario, Canada.

Any forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include all statements regarding WorldHeart's technology platform and reliance on key executives, as well as other statements that can be identified by the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "should," "seeks," "plans," "anticipates," or "intends" or the negative of those terms, or by discussions of strategy or intentions. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation: WorldHeart's need for additional capital in the future; risks in product development and market acceptance of and demand for WorldHeart's products; delisting from the NASDAQ Stock Market if compliance with the listing standards is not regained; and other risks detailed in WorldHeart's filings with the U.S. Securities and Exchange Commission, including without limitation its Annual Report on Form 10-KSB/A for the year ended December 31, 2007 and its Quarterly Report on Form 10-Q/A for the quarter ended March 31, 2008 and its Quarterly Reports on Form 10-Q for the quarters ended June 30, 2008 and September 30, 2008.


'/>"/>
SOURCE World Heart Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. WorldHeart Submits IDE Application for a Pivotal Bridge-to-Transplant Study of the Levacor(TM) VAD
2. WorldHeart Regains Compliance With the Minimum Bid Price Rule
3. WorldHeart Receives Notice From the NASDAQ Stock Market Regarding Non-Compliance With Marketplace Rule 4310(c)(7)
4. WorldHeart Announces Effectiveness of Reverse Stock Split
5. WorldHeart Receives Favorable Decision to Continue NASDAQ Listing
6. WorldHeart Receives Non-Compliance Letter From NASDAQ Stock Market
7. WorldHeart Announces Voluntary Delisting from the Toronto Stock Exchange
8. WorldHeart Announces Possible Delisting Action by NASDAQ
9. WorldHeart Notified of TSX Delisting Review
10. WorldHeart Appoints David Pellone Chief Financial Officer
11. WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors ... on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, ... to helping service members that have been wounded in battle and their families. Venture ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology: